Jonathan Wren to Cell Line, Tumor
This is a "connection" page, showing publications Jonathan Wren has written about Cell Line, Tumor.
Connection Strength
0.324
-
ELTD1, a potential new biomarker for gliomas. Neurosurgery. 2013 Jan; 72(1):77-90; discussion 91.
Score: 0.079
-
EWI2 prevents EGFR from clustering and endocytosis to reduce tumor cell movement and proliferation. Cell Mol Life Sci. 2022 Jun 30; 79(7):389.
Score: 0.038
-
EWI2 promotes endolysosome-mediated turnover of growth factor receptors and integrins to suppress lung cancer. Cancer Lett. 2022 06 28; 536:215641.
Score: 0.037
-
MicroRNA-195 controls MICU1 expression and tumor growth in ovarian cancer. EMBO Rep. 2020 10 05; 21(10):e48483.
Score: 0.034
-
KRCC1: A potential therapeutic target in ovarian cancer. FASEB J. 2020 02; 34(2):2287-2300.
Score: 0.032
-
Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model. J Cell Mol Med. 2020 01; 24(2):1738-1749.
Score: 0.032
-
A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer. BMC Cancer. 2019 May 06; 19(1):423.
Score: 0.031
-
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1. J Clin Invest. 2016 Feb; 126(2):706-20.
Score: 0.024
-
Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression. BMC Cancer. 2010 Dec 06; 10:672.
Score: 0.017